Skip to main content
Clinical Trials/DRKS00017896
DRKS00017896
Completed
Not Applicable

Predictors of psoriasis on response to systemic therapy - PREDICT

AbbVie Deutschland GmbH & Co. KG0 sites381 target enrollmentNovember 18, 2019
ConditionsL40Psoriasis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
L40
Sponsor
AbbVie Deutschland GmbH & Co. KG
Enrollment
381
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 18, 2019
End Date
January 12, 2018
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adult patients (\= 18 years) with moderate to severe plaque psoriasis (defined by the European Consensus 2011 \[5]) and present indication for conventional systemic psoriasis treatment (fumaric acid ester, MTX, cyclosporine, etc.) who are naive (untreated) to conventional psoriasis system therapy at the time of initiation of observation.

Exclusion Criteria

  • Patients who have already been treated with systemic psoriasis medications, i.e. are not naive to systemic psoriasis therapy and/or patients who are receiving PUVA therapy and/or patients who cannot or do not wish to sign the informed consent form

Outcomes

Primary Outcomes

Not specified

Similar Trials